Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/overview-of-the-efficacy-of-cetuximab-in-recurrent-and-or-metastatic-eEVmQU5OQ3
References (48)
-
C. Ritter, C. Arteaga (2003)
The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.Seminars in oncology, 30 1 Suppl 1
-
J. Mendelsohn (1997)
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 12 Pt 2
-
RS Herbst, M Arquette, DM Shin (2005)
Epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck: a phase II, multicenter study, 23
-
B. Burtness, M. Goldwasser, W. Flood, B. Mattar, A. Forastiere (2005)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 34
-
R. Herbst, M. Arquette, D. Shin, K. Dicke, E. Vokes, N. Azarnia, W. Hong, M. Kies (2005)
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 24
-
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)
Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 55
-
J. Vermorken, J. Bourhis, J. Trigo, M. Kies, X. León, M. Mueser, N. Amellal, A. Schueler, J. Baselga (2005)
Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapiesJournal of Clinical Oncology, 23
-
Luiz Kowalski, A. Carvalho (2000)
Natural history of untreated head and neck cancer.European journal of cancer, 36 8
-
(2001)
Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx -
A. Forastiere, B. Metch, D. Schuller, J. Ensley, L. Hutchins, P. Triozzi, J. Kish, S. McClure, E. VonFeldt, S. Williamson (1992)
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 8
-
N. Keldsen (1987)
Cisplatin as second line chemotherapy in advanced or recurrent squamous cell carcinoma of head and neck region.Acta oncologica, 26 5
-
SP Schantz, LB Harrison, A Forastiere (2001)
Cancer. Principles and Practice of Oncology -
V. Gebbia, R. Valenza, A. Testa, N. Borsellino, G. Cannata, S. Restivo, R. Speciale, F. Ingria, G. Spadafora, N. Gebbia (1994)
Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.ORL; journal for oto-rhino-laryngology and its related specialties, 56 5
-
M. Christensen, M. Therkildsen, B. Hansen, H. Albeck, G. Hansen, P. Bretlau (2004)
Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomasEuropean Archives of Oto-Rhino-Laryngology, 249
-
J. Bourhis, F. Rivera, R. Mesía, A. Awada, L. Geoffrois, C. Borel, Y. Humblet, A. López-pousa, R. Hitt, M. Villegas, L. Duck, D. Rosine, N. Amellal, A. Schueler, A. Harstrick (2006)
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18
-
M. Moroni, L. Giannetta, G. Gelosa, S. Secondino, G. Chillura, E. Colombo, S. Siena (2003)
Second-Line Chemotherapy with Bleomycin, Methotrexate, and Vinorelbine (BMV) for Patients with Squamous Cell Carcinoma of the Head, Neck and Esophagus (SCC-HN&E) Pretreated with a Cisplatin-Containing Regimen: A Phase II StudyJournal of Chemotherapy, 15
-
K. Ang, B. Berkey, X. Tu, Huazhong Zhang, R. Katz, E. Hammond, K. Fu, L. Milas (2002)
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.Cancer research, 62 24
-
J. Trigo, R. Hitt, P. Koralewski, E. Díaz-Rubio, F. Rolland, R. Knecht, N. Amellal, E. Bessa, J. Baselga, J. Vermorken (2004)
Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
-
X Leon, R Hitt, M Constenla (2003)
A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) who are progressing while on a platinum‐based palliative chemotherapy [abstract], 22
-
Zhen Fan, Hideo Masui, Ian Altas, John Mendelsohn (1993)
Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.Cancer research, 53 18
-
H. Iro, F. Waldfahrer (1998)
Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patientsCancer, 83
-
J. Grandis, M. Melhem, W. Gooding, R. Day, V. Holst, M. Wagener, S. Drenning, D. Tweardy (1998)
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient SurvivalJournal of the National Cancer Institute, 90
-
E. Kaplan, P. Meier (1958)
Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 53
-
A. Forastiere, B. Burtness (2007)
Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 16
-
J. Baselga, J. Trigo, J. Bourhis, J. Tortochaux, H. Cortés-Funes, R. Hitt, P. Gascón, N. Amellal, A. Harstrick, A. Eckardt (2005)
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 24
-
L. Saltz, M. Kies, Jl Abbruzzesse, N. Azarnia, M. Needle, L. Saltz, J. Abbruzzese (2003)
The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances -
J Baselga, JM Trigo, J Bourhis (2002)
Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum‐based regimen [abstract] -
(2007)
Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy—results of a randomized phase III (EXTREME) study [abstract -
MS Kies, MA Arquette, L Nabell (2002)
Final report of the efficacy and safety of the anti‐epidermal growth factor antibody Erbitux (IMC‐C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract] -
S. Segaert, E. Cutsem (2005)
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology, 16 9
-
R. Herbst, C. Langer (2002)
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.Seminars in oncology, 29 1 Suppl 4
-
A. Iop, G. Cartei, A. Isaia (1998)
Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.Annals of oncology : official journal of the European Society for Medical Oncology, 9 2
-
Zhen Fan, Yang Lu, Xipu Wu, J. Mendelsohn (1994)
Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells.The Journal of biological chemistry, 269 44
-
(2004)
Safety profile of cetuximab in patients with metastatic colorectal cancer [abstract]. Presented at the 2004 ASCO Gastrointestinal Cancers -
C. Arteaga (2003)
Targeting HER1/EGFR: a molecular approach to cancer therapy.Seminars in oncology, 30 3 Suppl 7
-
F. Robert, M. Ezekiel, S. Spencer, R. Meredith, J. Bonner, M. Khazaeli, M. Saleh, D. Carey, A. Lobuglio, R. Wheeler, M. Cooper, H. Waksal (2001)
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 13
-
M. Merlano, Andrea Grimaldi, L. Bonelli, Rita Tatarek, R. Rosso (1985)
Failure of Second-Line Therapy to Modify Survival in Relapsed Squamous Cell Carcinoma of the Head and NeckTumori Journal, 71
-
JB Vermorken, J Bourhis, J Trigo (2005)
Cetuximab (Erbitux) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first‐line platinum‐based therapies [abstract] -
Shiqing Li, K. Schmitz, P. Jeffrey, Jed Wiltzius, P. Kussie, K. Ferguson (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.Cancer cell, 7 4
-
N. Hanna (2008)
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based TherapyYearbook of Oncology, 2008
-
G. Numico, M. Merlano (2002)
Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 13 2
-
X. León, R. Hitt, M. Constenla, A. Rocca, R. Stupp, A. Kovács, N. Amellal, E. Bessa, J. Bourhis (2005)
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.Clinical oncology (Royal College of Radiologists (Great Britain)), 17 6
-
C. Wikstrand, D. Bigner (1998)
Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha.Journal of the National Cancer Institute, 90 11
-
S. Segaert, J. Tabernero, O. Chosidow, T. Dirschka, J. Elsner, L. Mancini, T. Maughan, J. Morere, A. Santoro, A. Sobrero, E. Cutsem, A. Layton (2005)
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapiesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 3
-
G. Numico, M. Merlano (2002)
Second-line treatment with docetaxel after failure of a platinum-based chemotherapyin squamous-cell head andneck cancerAnnals of Oncology, 13
-
J. Bonner, P. Harari, J. Giralt, N. Azarnia, D. Shin, R. Cohen, Christopher Jones, R. Sur, D. Raben, J. Jassem, R. Ove, M. Kies, J. Baselga, H. Youssoufian, N. Amellal, E. Rowinsky, E. Rowinsky, K. Ang (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.The New England journal of medicine, 354 6
-
N. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, J. Mendelsohn (1995)
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.Clinical cancer research : an official journal of the American Association for Cancer Research, 1 11
-
C Porta, S Brugnatelli, E Patruno (2001)
Single‐agent vinorelbine (VRB) as second‐line treatment for advanced or recurrent squamous‐cell carcinoma of the head and neck (SCCHN) [abstract]
- Publisher
- Wiley
- Copyright
- Copyright © 2008 Wiley Subscription Services
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- DOI
- 10.1002/cncr.23442
- pmid
- 18481809
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Cancer – Wiley
Published: Jan 15, 2008
Keywords: ; ; ; ; ; ;